Exome sequencing experiences discoveries of Wider applications

Publisher: The Insight Partners

The exon is part of a genome which is responsible for making 1 or 2 percent of the entire genome of a person. All of the exon in a genome are together known as the exome. And thus, sequencing is of these is known as whole-exome sequencing. The whole-exome sequencing allows identifying the variations in the protein-coding sites of any gene compared to sequencing a few genes together. The whole-exome sequencing is preferred widely due to its property to identify a mutation in a single exon. Identifying mutation in at the original site makes whole-exome sequencing an efficient method and enable to identify possible disease-causing mutation.

The advancement in the field of genomics has led to a significant reduction in the time and cost of genome sequencing. The related cost of sequencing with different sequencing techniques and strategies are of interest as they influence the scope and scale of the genomic research studies. Thus, it makes whole-exome sequencing much-preferred method than whole-genome sequencing.

The advantages of exome sequencing have resulted in the reduction of time and cost to a great extent. Approximately 2% of the genome is sequenced by the WES method; however, it generally sequences the exon at a deeper level it sequence to 100X. The technique enables sequencing through a process where the DNA and RNA are hybridized with the protein-coding site and is isolated from the non-coding site. Also, the data required for 100X sequencing is approximately 5- 6GB, whereas, in genome sequencing, it is nearly 90GB. Thus, these factors offer lower data storage, faster, cheaper, and more accessible data analysis. Therefore, owing to the above-mentioned factors, it is estimated that the market for whole-exome sequencing is likely to grow significantly during the forecast period.

The whole-exome sequencing has been accepted as an advanced sequencing technique due to its advantages. Due to the benefits of whole-exome sequencing, it is used as a diagnostic tool in regular practice. The technique is mainly used to diagnose genetic diseases and cancer. The use of exome sequencing is offered genetic analysis that allows appropriate treatment, management, inheritance, and efficient decision making.

The whole-exome sequencing technique is used as it provides information on clinically covered all genes. The technique analyzes conditions for single gene and multi gene disorders. The whole-exome sequencing technique is considered ideal for targeted management of complex conditions such as epilepsy, ASDs, neuropathy, and other genetic diseases. In addition, the whole-exome sequencing allows complete analysis of nearly 23,000 genes in the human genome with the help of next-generation sequencing in a single run.

The whole-exome sequencing is a short-term substitute for receiving an image of a genome that is being coded. Whole-exome sequencing is attractive in the fields of research, diagnostics, and clinical setting. The whole-exome sequencing is used for identifying variants in both all the disease types and in SNPs associations and pharmacogenetics.

Thus, the wide application of the whole-exome sequencing in the field of molecular diagnostics and clinical diagnostics are likely to influence the growth of the market during the forecast period.

The global whole exome sequencing market by product & services segments was led by kits. In 2018, the kits segment held a largest market share of the whole exome sequencing market, by product & services. Also, the kits segment is expected to be the fastest growing segments of the market in 2027 owing to presence of a large number of manufacturers like Thermo Fisher Scientific, Illumina, etc. and also these kits are frequently used in various research processes that further is expected to propel growth of the whole exome sequencing market.

Organic and inorganic growth strategies were observed in global whole exome sequencing industry. The organic strategies which were conducted more compared to the inorganic strategies for the whole exome sequencing. For instance, in February, 2019, Bio-Rad Laboratories, Inc.’s QXDx AutoDG ddPCR System has been approved by the FDA. The QXDx AutoDG ddPCR System is designed to be flexible, allowing users to run either FDA-cleared in vitro diagnostic tests or lab developed tests on the platform.

The global Whole exome sequencing market accounted to US$ 755.68 Mn in 2018 and is expected to grow at a CAGR of 19.8% during the forecast period 2019 – 2027, to account to US$ 3,812.0 Mn by 2027.